Esophageal Cancer Clinical Trial

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Summary

The purpose of study is to evaluate the efficacy and safety of immunotherapy-drugs-are-boosting-survival/" >Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men & women ≥20 years of age
Histologically confirmed unresectable advanced or recurrent esophageal cancer
Refractory to or intolerant of standard therapy
ECOG Performance Status score 0 or 1
A life expectancy of at least 3 months

Exclusion Criteria:

Current or past history of severe hypersensitivity to any other antibody products
Patients with multiple primary cancers
Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment
Patients with active, known or suspected autoimmune disease

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

419

Study ID:

NCT02569242

Recruitment Status:

Completed

Sponsor:

Ono Pharmaceutical Co. Ltd

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 88 Locations for this study

See Locations Near You

Banner MD Anderson Cancer Center
Gilbert Arizona, 85234, United States
Georgetown University Med Ctr
Washington District of Columbia, 20007, United States
Orlando Health, Inc
Orlando Florida, 32806, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Duke Cancer Institute
Durham North Carolina, 27710, United States
Vanderbilt-Ingram Cancer Ctr
Nashville Tennessee, 37232, United States
The University Of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Odense University Hospital
Odense C , 5000, Denmark
RWTH Aachen University
Aachen , 52057, Germany
Charite Campus Virchow Klinikum
Berlin , D-133, Germany
University Hospital Heidelberg
Heidelberg , 69120, Germany
Universitatsklinikum Jena, Innere Medizin II
Jena , 07747, Germany
MVZ Mitte
Leipzig , 04103, Germany
University Of Mainz Medical Center
Mainz , 55131, Germany
Klinikum reechts der Isar, Technical University Munchen
Munich , 81675, Germany
HPG23
Bergamo , 24127, Italy
Fondazione Irccs Istituto Nazionale Tumori
Milan , 20133, Italy
Irccs Istituto Oncologico Veneto Iov
Padova , 35128, Italy
Aichi Clinical Site
Nagoya Aichi, 464-8, Japan
Aichi Clinical Site
Nagoya Aichi, 466-8, Japan
Aomori Clinical Site
Hirosaki Aomori, 036-8, Japan
Chiba Clinical Site
Kashiwa Chiba, 277-8, Japan
Ehime Clinical Site
Matsuyama Ehime, 791-0, Japan
Hokkaido Clinical Site
Sapporo Hokkaido, 003-0, Japan
Hokkaido Clinical Site
Sapporo Hokkaido, 060-8, Japan
Hyogo Clinical Site
Akashi Hyogo, 673-0, Japan
Hyogo Clinical Site
Kobe Hyogo, 650-0, Japan
Kanagawa Clinical Site
Isehara Kanagawa, 259-1, Japan
Kanagawa Clinical Site
Kawasaki Kanagawa, 216-0, Japan
Kanagawa Clinical Site
Yokohama Kanagawa, 236-0, Japan
Kanagawa Clinical Site
Yokohama Kanagawa, 241-8, Japan
Mie Clinical Site
Tsu Mie, 514-8, Japan
Miyagi Clinical Site
Sendai Miyagi, 980-8, Japan
Nagano Clinical Site
Saku Nagano, 385-0, Japan
Niigata Clinical Site
Nigatake Niigata, 951-8, Japan
Osaka Clinical Site
Osakasayama Osaka, 589-8, Japan
Osaka Clinical Site
Suita Osaka, 565-0, Japan
Osaka Clinical Site
Takatsuki Osaka, 569-0, Japan
Saitama Clinical Site
Hidaka Saitama, 350-1, Japan
Saitama Clinical Site
Kita-Adachi County Saitama, 362-0, Japan
Shizuoka Clinical Site
Suntou County Shizuoka, 411-8, Japan
Tochigi Clinical Site
Shimotsuke Tochigi, 329-0, Japan
Tokyo Clinical Site
Bunkyo-ku Tokyo, 113-0, Japan
Tokyo Clinical Site
Chuo-ku Tokyo, 104-0, Japan
Tokyo Clinical Site
Chuo-ku Tokyo, 104-8, Japan
Tokyo Clinical Site
Koto-ku Tokyo, 135-8, Japan
Tokyo Clinical Site
Meguro-ku Tokyo, 152-8, Japan
Tokyo Clinical Site
Minato-ku Tokyo, 105-8, Japan
Tokyo Clinical Site
Shinagawa-ku Tokyo, 142-8, Japan
Tokyo Clinical Site
Shinjuku-ku Tokyo, 160-8, Japan
Tokyo Clinical Site
Shinjuku-ku Tokyo, 162-8, Japan
Akita Clinical Site
Akita , 010-8, Japan
Chiba Clinical Site
Chiba , 260-0, Japan
Chiba Clinical Site
Chiba , 260-8, Japan
Fukuoka Clinical Site
Fukuoka , 812-8, Japan
Fukushima Clinical Site
Fukushima , 960-1, Japan
Hiroshima Clinical Site
Hiroshima , 734-8, Japan
Kagoshima Clinical Site
Kagoshima , 890-8, Japan
Kumamoto Clinical Site
Kumamoto , 860-8, Japan
Kyoto Clinical Site
Kyoto , 602-8, Japan
Kyoto Clinical Site
Kyoto , 606-8, Japan
Niigata Clinical Site
Niigata , 951-8, Japan
Osaka Clinical Site
Osaka , 537-8, Japan
Shizuoka Clinical Site
Shizuoka , 420-8, Japan
Busan Clinical Site
Busan , 49241, Korea, Republic of
Daegu Clinical Site
Daegu , 41404, Korea, Republic of
Daegu Clinical Site
Daegu , 41931, Korea, Republic of
Daejeon Clinical Site
Daejeon , 35015, Korea, Republic of
Gyeonggi-do Clinical Site
Gyeonggi-do , 13620, Korea, Republic of
Hwasun-Gun Clinical Site
Hwasun-Gun , 58128, Korea, Republic of
Seoul Clinical Site
Seoul , 03080, Korea, Republic of
Seoul Clinical Site
Seoul , 03722, Korea, Republic of
Seoul Clinical Site
Seoul , 05505, Korea, Republic of
Seoul Clinical Site
Seoul , 06351, Korea, Republic of
Seoul Clinical Site
Seoul , 06591, Korea, Republic of
Ulsan Clinical Site
Ulsan , 44033, Korea, Republic of
Changhua Clinical Site
Changhua , 500, Taiwan
Chiayi Clinical Site
Chiayi , 61363, Taiwan
Kaohsiung Clinical Site
Kaohsiung , 807, Taiwan
Kaohsiung Clinical Site
Kaohsiung , 82445, Taiwan
Kaohsiung Clinical Site
Kaohsiung , 83301, Taiwan
Keelung Clinical Site
Keelung , 20445, Taiwan
Taichung Clinical Site
Taichung , 40447, Taiwan
Tainan Clinical Site
Tainan , 704, Taiwan
Taipei Clinical Site
Taipei , 10048, Taiwan
Taipei Clinical Site
Taipei , 11217, Taiwan
Taoyuan Clinical Site
Taoyuan , 333, Taiwan
Velindre Cancer Centre
Cardiff Cardiganshire, CF142, United Kingdom
The Beatson West Of Scotland Cancer Centre
Glasgow Lanarkshire, G12 0, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

419

Study ID:

NCT02569242

Recruitment Status:

Completed

Sponsor:


Ono Pharmaceutical Co. Ltd

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.